ArticleAmerican journal of hematology2025
Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma.
Abstract read
In one paragraph
Article in American journal of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Regulation of immune checkpoint molecules in cancer immune evasion and therapy.Nature reviews. Cancer · 2026Review
- Unraveling the many faces of angioimmunoblastic T-cell lymphoma: clinical, pathological, and molecular heterogeneity.Annals of hematology · 2026Review
- Multi-omics analysis identifies GAA as an independent poor prognostic biomarker and candidate therapeutic target in angioimmunoblastic T-cell lymphoma.Frontiers in immunology · 2026Article
- L-Tetrahydropalmatine synergizes cytotoxic CD8Cell death discovery · 2025Article
- Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma.American journal of hematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors.
Alyssa BouskaDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID 0000-0003-1324-6678
Weiwei ZhangDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Sunandini SharmaDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Harald HolteDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Rauf A ShahDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Waseem G LoneDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID 0000-0003-3078-614X
Mahfuza Afroz SomaDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Ruimeng YangDepartment of Pathology, City of Hope National Medical Center, Duarte, California, USA.
Xuxiang LiuDepartment of Pathology, City of Hope National Medical Center, Duarte, California, USA.
Syed MehmoodDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Ravneet Singh ChawlaDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Luca Vincenzo CappelliDepartment of Pathology and Laboratory Medicine, Weil Cornell Medical College, New York, New York, USA.ORCID 0000-0001-8090-3880
Danilo FioreDepartment of Pathology and Laboratory Medicine, Weil Cornell Medical College, New York, New York, USA.
Qiang GongDepartment of Pathology, City of Hope National Medical Center, Duarte, California, USA.
Tayla B Heavican-ForalDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Jeffrey J CannatellaDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Catalina AmadorDepartment of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
Aiza ArifDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Lynette M SmithDepartment of Biostatistics, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Soon Thye LimDivision of Medical Oncology, National Cancer Centre Singapore/Duke-NUS Medical School, Singapore, Singapore.
Choon Kiat OngDivision of Medical Oncology, National Cancer Centre Singapore/Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0001-6402-4288
Andrew L FeldmanDepartment of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
Ming-Qing DuDepartment of Pathology, University of Cambridge, Cambridge, UK.
Anamarija M PerryDepartment of Pathology, University of Michigan, Ann Arbor, Michigan, USA.
Laurence de LevalInstitute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV) and University of Lausanne, Lausanne, Switzerland.
Timothy C GreinerDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Kai FuDepartment of Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Gunhild TrøenDepartment of Pathology, Oslo University Hospital, Oslo, Norway.
Daniel VodákDepartment of Pathology, Oslo University Hospital, Oslo, Norway.
Sigve NakkenDepartment of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway.
Jan DelabieToronto General Hospital: University Health Network (UHN), University of Toronto, Toronto, Ontario, Canada.
David WeinstockDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.ORCID 0000-0002-8724-3907
Stefano PileriEuropean Institute of Oncology IRCCS, Milan, Italy.
Antonella LaginestraEuropean Institute of Oncology IRCCS, Milan, Italy.
KyeongJin KimDepartment of Biomedical Sciences, College of Medicine, Inha University, Incheon, Republic of Korea.
Utpal PajvaniDepartment of Medicine, Columbia University, New York, New York, USA.
Julie M VoseDepartment of Hematology and Oncology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Dennis D WeisenburgerDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Steven M HorwitzLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Sandeep DaveDepartment of Medicine, Duke University, Durham, North Carolina, USA.
Joseph KhouryDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Giorgio InghiramiDepartment of Pathology and Laboratory Medicine, Weil Cornell Medical College, New York, New York, USA.
Wing C ChanDepartment of Pathology, City of Hope National Medical Center, Duarte, California, USA.
Javeed IqbalDepartment of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTransgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3MPreclinical Models and Therapeutics CoreP01CA229100 · NCI · MAYO CLINIC ARIZONA · PI SCOTT, DAVID WILLIAM · 2018 to 2022
$10.2MCooperative role of TET2 and IDH2 mutations in angioimmunoblastic T-cell lymphomagenesisR01CA251412 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI IQBAL, JAVEED, SONG, JOO · 2021 to 2025
$2.4MMolecular diagnostic and prognostic signatures for PTCLUH3CA206127 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI CHAN, WING C., IQBAL, JAVEED · 2019 to 2021
$864kMolecular diagnostic and prognostic signatures for PTCLUH2CA206127 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI CHAN, WING C., IQBAL, JAVEED · 2017 to 2018
$397kDevelopment of a Novel Clinical Diagnostic Assay for Peripheral T-cell Lymphoma (PTCL)R41CA221466 · NCI · HEALTHCHART, LLC · PI CHAN, WING C., IQBAL, JAVEED · 2018 to 2018
$299kLeukemia and Lymphoma Society, SCOR TRP-6129-04NCI NIH HHS CA206127-02NCI NIH HHS CA229100NCI NIH HHS P01 CA229100NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA033572NCI NIH HHS P30CA033572NCI NIH HHS R01 CA251412NCI NIH HHS R01CA251412NCI NIH HHS R41 CA221466NCI NIH HHS R41CA221466-01A1NCI NIH HHS UH2 CA206127NCI NIH HHS UH3 CA206127Norges Forskningsråd 218241Norges Forskningsråd 221580
Abstract
Nodal follicular helper T-cell (T
Indexed as
Immunoblastic LymphadenopathyLymphoma, T-CellTranscriptomeAgedDioxygenasesDNA-Binding ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA MethylationDNA Methyltransferase 3AEpigenesis, GeneticExome SequencingFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGenomicsHumansDioxygenasesDNA-Binding ProteinsDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanProto-Oncogene ProteinsTET2 protein, humancancer geneticsgenomics and transcriptomicslymphomaangioimmunoblastic T‐cell lymphoma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.